Russell D Cohen, MD: Understanding the Role of Biosimilars in Healthcare
Russell D Cohen, MD, explains how biosimilars represent an opportunity to expand access and reduce the financial burden of high-cost biologics.
Stay updated with breaking news from Biosimilar Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Russell D Cohen, MD, explains how biosimilars represent an opportunity to expand access and reduce the financial burden of high-cost biologics.
The labeling of biosimilar products as “interchangeable” may be important in order to gain acceptance and use in the medical community. This article provides important information...
Sandoz has launched a new antibiotic production plant in Austria along with a biosimilar development center in Germany. The units are in line with the firm’s aim to strengthen sustainable development and supply of critical medicines in Europe and other regions of the world.
On September 18, 2023, the FDA issued a new draft guidance “Labeling for Biosimilar and Interchangeable Biosimilar Products,” updating the previous labeling guidance “Labeling for...
Interchangeable biosimilar products would not be allowed to disclose or explain their interchangeability designations in their products’ labels under FDA’s new draft guidance. ...